Cetraxal® Plus 3mg/ml + 0.25 mg/ml - AOE & AOMT - Otic solution Rx

Cetraxal® Plus 3mg/ml + 0.25 mg/ml - AOE & AOMT - Otic solution Rx
Product Description

Unique combination "ciprofloxacin 3 mg + Fluocinolone 0.25 mg" topical solution 

Indication: Acute otitis externa and acute otitis media with perforated eardrums in adults and pediatric patients. 
Dosage regimen: B.I.D x 7 days
Presentation of multi-dose 10 ml and unit dose vials (14 vials)

Laboratorios Salvat, S.A.

  • ES
  • 2016
    On CPHI since
  • 4
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Drug delivery device Supplier/Manufacturer
Licensee
Manufacturer/Innovator
OTC
Pharmaceutical company
Primary activities
Contract Manufacturer
Contract Research Organisation
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
Specifications

Laboratorios Salvat, S.A.

  • ES
  • 2016
    On CPHI since
  • 4
    Certificates
  • 250 - 499
    Employees
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Drug delivery device Supplier/Manufacturer
Licensee
Manufacturer/Innovator
OTC
Pharmaceutical company
Primary activities
Contract Manufacturer
Contract Research Organisation
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)

More Products from Laboratorios Salvat, S.A. (21)

  • Bimeox® 0.3mg/ml - Glaucoma (Preservative-free) - Rx

    Product Bimeox® 0.3mg/ml - Glaucoma (Preservative-free) - Rx

    Bimeox® Bimatoprost 0.3 mg/ml, a well-known prostaglandin analogue eye drop, preservative-free, presented in single-dose vials using our Blow-Fill-Seal Technology.

    • Innovative format in single-dose vials • Preservative-free for better tolerability • Sterile until ope...
  • Tanolux® 50 ug/ml - Glaucoma - Rx

    Product Tanolux® 50 ug/ml - Glaucoma - Rx

    Tanolux® Latanoprost 50 ug/ml, a well-known prostaglandin analogue eye drop, presented in single-dose vials using our Blow-Fill-Seal Technology.

    • Innovative format in single-dose vials • No cold chain required, easy to store & carry • Vey low solvents concentration vs ...
  • Tebarat 0.5 mg/ml - Allergic conjunctivitis - single-dose vials eye drops - Rx

    Product Tebarat 0.5 mg/ml - Allergic conjunctivitis - single-dose vials eye drops - Rx

    Tebarat 0.5 mg/ml eye drops are indicated for the treatment and prevention of allergic conjunctivitis. Treatment and prevention of seasonal allergic conjunctivitis symptoms in adults and children aged 4 years and over.Treatment of non-seasonal (perennial) allergic conjunctivitis symptoms in adults and chil...
  • Relive® Sicca - Dry eye - Nanoemulsion eye drops - MD

    Product Relive® Sicca - Dry eye - Nanoemulsion eye drops - MD

    Symptomatic relief of moderate to severe dry eye syndrome, using IMPACT-SVT® nanoemulsion patent drug delivery technology. 

    Holistic approach for a multi-factorial pathology: anti-inflammatory, antioxidant, mucogenic, mucoadhesion, lubrication, and anti-evaporative activity. •...
  • Relive® Total Care - Lubrication + UV protection eye drops - MD

    Product Relive® Total Care - Lubrication + UV protection eye drops - MD

    Regenerate, protect against UV radiation, and lubricate. Eye tears, specially designed for after surgery.
    • 20 unit dose vials of 0,4 ml • Preservative free • With Actinoquinol 0,3%, Cyanocobalamin 0,05%, PVPK 30 1,5% 
  • Relive® - Day & Night eye drops - MD

    Product Relive® - Day & Night eye drops - MD

    RELIVE® DRY EYE - 8 Hours of Dry Eye Relief
    RELIVE® NIGHT - 12 Hours of Long-lasting Dry Eye Relief • Preservative-Free • Phosphate-Free • Single-dose vials, very Convenient format
  • Ekzem® 0.25 mg/ml - Otic eczema - single-dose vials - otic solution Rx

    Product Ekzem® 0.25 mg/ml - Otic eczema - single-dose vials - otic solution Rx

    Fluocinolone acetonide, topical solution. Ekzem is indicated for the treatment of otic eczema in adults. Demonstrated efficacy and safety in clinical studies 
    Available in unit dose vials of 0.4 ml each. (30 vials x box)
  • Cristalmina® - Antiseptic - OTC

    Product Cristalmina® - Antiseptic - OTC

    Chlorhexidine digluconate 1% Cristalmina®, offers a quick action and long-lasting effect.
    Cristalmina®, the antiseptic leader in the Spanish market, is the most complete, for the whole family 

    Indication: Minor skin wounds and burns, even for the umbilical cord in newborns.
  • Cetraxal® Otico 2mg/ml - AOE - Otic solution Rx

    Product Cetraxal® Otico 2mg/ml - AOE - Otic solution Rx

    Ciprofloxacin 3 mg, topical solution. 

    Indication: AOE 
    Dosage:  B.I.D x 7 days.
    Presentation: Available in multidose 10ml  and unit dose vials (15 vials).
  • Cetraflux 3 mg/ml - Eye infection - single-dose vials eye drops - Rx

    Product Cetraflux 3 mg/ml - Eye infection - single-dose vials eye drops - Rx

    Cetraflux 3 mg/ml eye drop solution is indicated for the local treatment of the following infections caused by strains sensitive to ciprofloxacin, in adults, neonates (0-27 days), infants (aged 28 days to 23 months), children (aged 2-11 years), adolescents (aged 12-16 years). Available in single dose conta...
  • Monolitum Flas 15 mg & 30 mg ODT - PPI - Rx

    Product Monolitum Flas 15 mg & 30 mg ODT - PPI - Rx

    Monolitum Flas 15mg / 30mg - ODT formulation - Pack of 14, 28, 56 orally disintegrating tablets

    Monolitum Flas 30mg - Acute treatment of duodenal ulcer, gastric ulcer and oesophagitis due to gastro-oesophageal reflux. Eradication of Helicobacter pylori in patients with duodenal ulcer and benig...
  • Urosens range - Urinary infections - FS

    Product Urosens range - Urinary infections - FS

    "The most complete range for each type of cystitis"

    Urosens: MAINTENANCE in occasional urinary infections.
    Urosens forte: ADJUVANT in urinary infectionsUrosens mannose: MAINTENANCE & ADJUVANT in urinary infections, very recurrent urinary infection

Laboratorios Salvat, S.A. resources (2)

  • News Laboratorios Salvat inicia un estudio pediátrico pionero en Europa con su fármaco innovador SVT-15473, para el tratamiento de la inflamación y dolor tras la cirugía ocular

    • Los ensayos clínicos fase III realizados en adultos confirman la eficacia y el excelente perfil de seguridad de SVT-15473 clobetasol oftálmico, formulado con IMPACT-SVT® tecnología patentada de nanoemulsiones, para el tratamiento de la inflamación y el dolor después de una cirugía ocular.
    • Es el primer estudio clínico que se realiza en paciente pediátrico con un corticoide tópico oftálmico en toda Europa.
    • Con el nuevo estudio que se inicia ahora y que se llevará a cabo en seis hospitales españoles se espera demostrar también su seguridad en pacientes pediátricos de 0 a 3 años.
    • Con este proyecto, que ha supuesto una inversión global de más de 20 millones de euros, Laboratorios Salvat da un paso más en su estrategia de afianzarse como un actor clave en el área de oftalmología a nivel internacional.
  • Video SVT-15473 + IMPACT-SVT® Nanoemulsion technology

    Salvat has developed IMPACT-SVT®, a patented nanoemulsion drug delivery technology that improves drug mucus penetration and bio-adhesion, providing excellent ocular comfort.

    IMPACT-SVT® made it possible to develop SVT-15473, using the strongest corticosteroid in the global market.